Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 285 full-time employees. The company went IPO on 2018-09-14. The firm is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The firm mainly conducts its business in the domestic market.
02552.HK stock price ended at $3.25 on 金曜日, after dropping 4.69%
On the latest trading day Jan 16, 2026, the stock price of 02552.HK fell by 4.69%, dropping from $3.41 to $3.25. During the session, the stock saw a volatility of 6.56%, with prices oscillating between a daily low of $3.20 and a high of $3.41. On the latest trading day, the trading volume for 02552.HK rose by 3.2M shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 5.3M shares were traded, with a market value of approximately $3.2B.